ESC Premium Access

Identifying and managing complications of atrial fibrillation

Event: ESC CONGRESS 2019
Topic: Treatment
Session type: Moderated Posters
Date: 1 September 2019
Time: 10:05 - 10:55

Congress Session

6 presentations in this session

Stroke severity and subsequent mortality are worse with atrial fibrillation than in patients without atrial fibrillation

Speaker: Ms N. Vinding (Copenhagen, DK)
Thumbnail

Comparative safety and effectiveness of standard doses of apixaban versus dabigatran, rivaroxaban, and VKAs in non-valvular atrial fibrillation patients in France: the NAXOS study

Speaker: Professor N. Danchin (Paris, FR)
Thumbnail

Resumption of anticoagulant treatment in patients with atrial fibrillation following gastrointestinal bleeding: a nationwide cohort study

Speaker: Miss D. Rajan (Copenhagen, DK)
Thumbnail

ETNA-AF Europe: First 1-year follow-up snapshot analysis of more than 7,500 AF patients treated with edoxaban in routine clinical practice

Speaker: Professor R. De Caterina (Pisa, IT)
Thumbnail

Left atrial dimension and risk of cardiovascular outcomes in patients with and without atrial fibrillation: a systematic review and meta-analysis

Speaker: Doctor P. Meyre (Basel, CH)
Thumbnail

Right atrial low voltage zone as a novel predictor of sinus node dysfunction in patients with non-paroxysmal atrial fibrillation

Speaker: Doctor T. Kondo (Hiroshima, JP)
Thumbnail

6 speakers from this session

Ms Naja Emborg Vinding

Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)
0 follower

Professor Nicolas Danchin

AP-HP - European Hospital Georges Pompidou, Paris (France)
13 presentations
0 follower

Miss Deepthi Rajan

Herlev and Gentofte Hospital, Copenhagen (Denmark)
0 follower

Professor Raffaele De Caterina

University Hospital of Pisa, Pisa (Italy)
26 presentations
1 follower

Doctor Pascal Meyre

University Hospital Basel, Basel (Switzerland)
0 follower

Doctor Takehito Kondo

Hiroshima Heart Center, Hiroshima (Japan)
0 follower

This platform is supported by

logo Novo Nordisk